(Q73157656)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9071477%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9071477%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

main subject

Paget's disease of bone

1 reference

J P Devogelaer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9071477%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

J Malghem

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9071477%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

P Stasse

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9071477%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

C Nagant de Deuxchaisnes

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9071477%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 March 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9071477%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9071477%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9071477%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9071477%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

259-261

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9071477%20AND%20SRC:MED&resulttype=core&format=json

Mineralisation defects with pamidronate therapy for Paget's disease

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900368-7

7 January 2021

Effects of ethane-1 hydroxy-1, 1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900368-7

7 January 2021

Long-term effects of intravenous pamidronate in fibrous dysplasia of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900368-7

7 January 2021

Etidronate and the risk of fractures

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900368-7

7 January 2021

Skeletal safety of tiludronate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900368-7

7 January 2021

Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900368-7

7 January 2021

Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2896%2900368-7

7 January 2021

10.1016/S8756-3282(96)00368-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9071477%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference